ARCHIVES

Cytogen Corp.’s Imaging Agent ProstaScint Added to NCCN Prostate Cancer Guidelines.

This article is from The Cancer Letter archive.

Vol. 26 No. 13 | March 31, 2000

Download PDF Visit The Full Archive

Related Articles

Patenting the Gene: Cancer Advocates and Industry Diverge on Myriad Ruling

June 14, 2013

CCOP Reponses So Far Indicates application To Total 150-200

August 27, 1982

Central Line Safety Intervention Lowers Patient Infection Rate

October 25, 2013

ACCP Publishes Guidelines Recommending Low-Dose CT

May 31, 2013

Onward to 2010? NCI promises faster progress for more money.

May 20, 2005

Clinical Trials Approved By NCI Last Month Are Listed

February 28, 2003